# A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma

> **NCT00783289** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 35 (actual)

## Conditions studied

- Asthma

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** Benralizumab 25 mg
- **BIOLOGICAL:** Benralizumab 100 mg
- **BIOLOGICAL:** Benralizumab 200 mg

## Key facts

- **NCT ID:** NCT00783289
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11-14
- **Primary completion:** 2009-11-17
- **Final completion:** 2009-11-17
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2019-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00783289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00783289, "A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00783289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*